Roanoke Heart Institute | Roanoke, VA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Additional Inclusion/Exclusion criteria may apply per protocol
Primary purpose
Allocation
Interventional model
Masking
300 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Medical Monitor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal